Brought to you by 
XTL plans to develop Dov's bicifadine for neuropathic pain
17 Aug 2007
Executive Summary
Giving itself a chance to focus on other programs, Dov Pharmaceutical (CNS drug candidates) has licensed infectious disease firm XTL Biopharmaceuticals exclusive worldwide rights to Phase III bicifadine, which XTL plans to develop for neuropathic pain.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
XTL plans to develop Dov's bicifadine for neuropathic pain
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice